Key result
A 92-year-old man with atrial fibrillation and mild renal dysfunction developed a severe intracranial hemorrhage after four months of rivaroxaban therapy.
Case Report (n=1)
No
This case highlights the risk of severe intracranial hemorrhage associated with rivaroxaban, particularly in elderly patients with renal dysfunction.
May warrant vigilance for ICH in elderly AF patients with renal impairment on rivaroxaban; hypothesis-generating case report requiring confirmation.
Rivaroxaban is a newer anticoagulant initially approved by the Food and Drug Administration to treat nonvalvular atrial fibrillation. Rivaroxaban has several characteristics that are more favorable than warfarin. One of the characteristics is decreased risk of hemorrhage. We report one of the first case reports of severe intracranial hemorrhage associated with rivaroxaban in an elderly patient with decreased renal function. We aim to alert emergency medicine providers regarding the likelihood of encountering these patient as newer anticoagulants rise in popularity.
No takes yet. Share an insight, caveat, or question.
Lo et al. (2014) conducted a case report in Atrial fibrillation and intracranial hemorrhage (n=1). Rivaroxaban was evaluated on Intracranial hemorrhage. A 92-year-old man with atrial fibrillation and mild renal dysfunction developed a severe intracranial hemorrhage after four months of rivaroxaban therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: